Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TKNO with free AI briefings, catalyst countdowns, and dilution alerts.

TKNO · Alpha Teknova, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$16.6M Cash on Hand
56.8mo Cash Runway
Follow TKNO by email Get an email when TKNO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TKNO, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Benzgalantamine
FDA approved Jul 2024 · Zunveyl
Alzheimer Disease Phase 4 · NCT07633470 Recruiting
Zorifertinib (AZD3759) Non-small Cell Lung Cancer Phase 2/3 · NCT03653546 Completed
Birinapant High Grade Fallopian Tube Serous Adenocarcinoma Phase 1/2 · NCT02756130 Withdrawn
[14C]Zorifertinib Oral Formulation EGFR Mutant Advanced Non-small Cell Lung Cancer Phase 1 · NCT07620951 Completed
[211At]NaAt DTC - Differentiated Thyroid Cancer Phase 1 · NCT07287748 Recruiting

Also used in these trials (approved or third-party drugs, not TKNO's own candidates): Pembrolizumab, Erlotinib Hydrochloride, Gefitinib, Trifluridine And Tipiracil, Carboplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TKNO holds $16.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $874,500/quarter from operations, an estimated runway of 56.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TKNO files for a raise →

👥 Who Owns TKNO

Insiders 37.4% Institutions (121 holders) 62.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
Telegraph Hill Partners IV, L.P.
10% owner
Insider 22,829,504 36.29% 2024-07-12
Stephen Gunstream
President and CEO, Director · +822,663 options
Insider 269,497 0.43% 2026-02-15
Matthew Lowell
Chief Financial Officer · +340,857 options
Insider 168,376 0.27% 2026-02-15
Brett Robertson
Director · +55,000 options
Insider 107,472 0.17% 2025-06-17
Alexander Vos
Director · +55,000 options
Insider 102,472 0.16% 2025-06-17
Ken Gelhaus
Chief Commercial Officer
Insider 22,924 0.04% 2023-11-30
Martha J Demski
Director · +55,000 options
Insider 12,000 0.02% 2026-07-14
Robert McNamara
Director
Insider 9,357 0.01% 2023-06-02
Paul David Grossman
Director
Insider 9,212 0.01% 2022-08-15

Share count 62,903,130 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TKNO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TKNO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.